What is the evidence to support the use of lipoprotein (a) levels as a target of therapy?
Moderate primary elevations of triglycerides, non HDL-C (total cholesterol HDL-C), and, if measured, apolipoprotein B can improve selection of those at increased risk, but no available RCT evidence supports lipoprotein (a) levels as a target of therapy.